Molecular Therapy

Top Research Topics at Molecular Therapy?

The concepts of Molecular biology, Genetic enhancement, Immunology, Virology and Cancer research are tackled in the journal. Molecular Therapy explores issues in Molecular biology which can be linked to other research areas like Gene, Transgene, Transduction (genetics), Transfection and In vivo. Molecular Therapy focused on Gene research conducted under the discipline of Genetics.

Molecular Therapy focused on Transduction (genetics) research but expanded to cover Cell biology. Genetic enhancement research featured in the journal incorporates concerns from various other topics such as Gene expression, Viral vector, Internal medicine and Haematopoiesis. The research on Immunology tackled can also make contributions to studies in the areas of Cytotoxic T cell and Stem cell.

In it, Bone marrow and Transplantation are investigated in conjunction with one another to address concerns in Stem cell research. Vector (molecular biology) and Cell culture are some topics wherein Virology research discussed in Molecular Therapy have an impact. Some problems in Cancer research that were presented in the journal overlapped with concepts under Cancer cell, Cancer, Metastasis and Immunotherapy.

• Molecular biology (29.50%)
• Genetic enhancement (24.03%)
• Immunology (22.93%)

What are the most cited papers published in the journal?

• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 (1655 citations)
• Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells (946 citations)
• Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. (907 citations)

Research areas of the most cited articles at Molecular Therapy:

The most cited papers primarily tackle Molecular biology, Genetic enhancement, Immunology, Virology and Cell biology. The most cited papers with studies in Molecular biology featured incorporate elements of Cell culture, Transfection, Gene expression, Transgene and In vivo. The journal publications hold forums on Genetic enhancement that merge themes from other disciplines such as Vector (molecular biology), Viral vector and Transduction (genetics).

What topics the last edition of the journal is best known for?

• Gene
• Internal medicine
• Enzyme

The previous edition focused in particular on these issues:

Molecular Therapy covers a variety of subjects, including Cancer research, Cell biology, Genetic enhancement, Immune system and Virology. Concepts in CD8, as well as related topics in Cytotoxic T cell, are covered in the Cancer research research presented in Molecular Therapy. The studies in Cell biology featured incorporate elements of RNA and Gene knockdown.

Research in Genetic enhancement tackled falls within the umbrella of Gene. The discussions emphasized the topic of Immune system in an attempt to further explore the field of Immunology. The work on Virology tackled in it brings together disciplines like Coronavirus disease 2019 (COVID-19) and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The most cited articles from the last journal are:

• Current Clinical Applications of In Vivo Gene Therapy with AAVs. (37 citations)
• A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. (22 citations)
• A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. (22 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Molecular Therapy (based on the number of publications) are:

• James M. Wilson (141 papers) published 3 papers at the last edition, 2 more than at the previous edition,
• Mark A. Kay (122 papers) published 2 papers at the last edition, 1 more than at the previous edition,
• David T. Curiel (91 papers) absent at the last edition,
• Guangping Gao (89 papers) published 1 paper at the last edition the same number as at the previous edition,
• Luigi Naldini (87 papers) published 1 paper at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Molecular Therapy (based on the number of publications) are:

• University of Pennsylvania (378 papers) published 21 papers at the last edition, 9 more than at the previous edition,
• University of Florida (285 papers) published 8 papers at the last edition, 1 more than at the previous edition,
• National Institutes of Health (271 papers) published 18 papers at the last edition, 16 more than at the previous edition,
• University of Washington (245 papers) published 6 papers at the last edition, 4 more than at the previous edition,
• University of North Carolina at Chapel Hill (213 papers) published 6 papers at the last edition, 2 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 9.12% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 23.89% were posted by at least one author from the top 10 institutions publishing in the journal. Another 8.85% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 20.94% of all publications and 46.31% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.